• A leading pharmaceutical organization’s team was participating in an annual congress and wanted to be sure that they could capture and share information/insights gathered during the event’s scientific lectures and 1:1 KOL meetings. In addition, they wanted their MedComm colleagues to be able to review, assess, and determine if there was relevant information or trends that need to be highlighted and shared with their leadership team or communicated more broadly to Medical/Commercial teams.

    Read More

  • A leading pharmaceutical organization’s patient advocacy team was tasked with securing insights and perspectives from a group of global patient advocates located in six different countries about a newly approved drug therapy and its related patient education materials. The team had already established an initial relationship with these individuals at a live meeting earlier in the year, and they wanted to keep the conversation going through a virtual advisory steering committee. Specifically, this ongoing advisory board would provide direction and guidance on the pre-market development plans regarding a new treatment for a rare disease, inclusive of all factors that might impact program milestones in preparation for approval and launch.

    Read More

  • A leading pharmaceutical organization’s medical affairs’ team was tasked with securing insights and perspectives from physician and nurse KOLs located across the United States about a Phase IV study’s potential design, methodology, logistical and operational challenges, and the varying institutional setting challenges that may exist for conducting the study. Specifically, they wanted to gather expert insights to assess the ability to successfully utilize a drug, previously prescribed to be administered in a high-acuity setting, now being considered for prescribing in a low-acuity setting.

    Read More

  • A leading pharmaceutical organization’s medical affairs team was committed to gathering ongoing actionable insights from oncologists located throughout the United States about the latest trial data for a new combination therapy for treating a type of respiratory cancer. Specifically, they wanted to gather prescribers’ insights to assess their evaluation of ongoing safety and efficacy data and the potential impact to first-line treatment decision-making.

    Read More

  • A leading pharmaceutical organization’s medical affairs team was committed to gathering critical insights from physicians located throughout Latin America about their preferences and perceptions of available therapies for treating bi-polar patients. Specifically, they wanted to gather prescribers’ insights to assess their preferences for bi-polar therapies, to ascertain why they select one brand over the other, what the organization could do to provide them with the information they need, and how the introduction of new therapies into the category might impact their treatment decision-making.

    Read More

  • A leading pharmaceutical organization’s commercial leadership team was committed to improving the process of conducting competitive market research. They wanted to ask very poignant questions of prescribers to assess their preferences for therapies which treat asthma, to ascertain why they select one brand over the other, and how the introduction of new therapies into the category might impact their treatment decision-making.

    Read More

  • Through educational support and mentoring initiatives, pharmaceutical organizations have long played a role in providing support to the ongoing education and training of clinical professionals. A leading pharmaceutical organization’s commercial team was purposed with conducting a discussion with a group of graduating fellows. This case study examines how the commercial team innovatively addressed their objectives.

    Read More

  • Annual internal strategic planning and execution requires a coordinated and collaborative discussion, tactical decision-making, and the review of vast quantities of documentation. The outcomes from these internal engagements will provide a map of efforts and related timelines that will include participation from countless individuals and teams throughout the organization. A leading pharmaceutical organization’s internal medical management team was purposed with conducting this annual engagement process – a process which requires a seamless engagement of individuals located around the globe. This case study examines how the medical affairs team innovatively addressed their objectives.

    Read More

  • Recently more companies have been turning to online discussion platforms to strengthen their market insights, reduce cost, and reduce time to market. This paper covers common ROI results cited by Within3 clients who have used the virtual platform to gain critical information for their businesses.

    Read More

  • A leading pharmaceutical organization’s medical affairs team purposed with acquiring expert feedback across Ukraine. Further, the team needed an alternative meeting option that would prove both cost-effective and logistically friendly. This case study examines how they took an innovative approach to achieving the necessary engagement outcomes.

    Read More

  • Learn how a leading pharmaceutical organization’s commercial team took an innovative approach to achieving necessary physician and clinical engagement outcomes.

    Read More

  • Acquiring expert clinical insights and perspectives is critical throughout the lifecycle of a drug. The findings often serve to have cross-organizational impact – shaping both medical affairs and commercial team decision-making and related efforts. A leading pharmaceutical organization’s medical affairs team was purposed with acquiring multi-touchpoint feedback about these types of patient-centric topics on the subject of lymphatic blood-based cancer. This case study examines how they took an innovative approach to achieving the necessary engagement outcomes.

    Read More

  • Purposeful discussions between pharmaceutical organizations and healthcare professionals (HCPs) are critical throughout the lifecycle of a compound. Discover how a clinical development team within a leading pharmaceutical organization, that was purposed with acquiring feedback on a biological agent which would serve as a therapeutic target, took an innovative approach to gaining increased KOL participation and feedback, while reducing costs by nearly 60%. The feedback would entail HCP perspectives on single ascending dose and multiple dose study design, opinions on trial timing, design, population, and other key study elements.

    Read More

  • While social media staples such as Twitter, Facebook, LinkedIn, and others have become standard marketing procedure for most pharmaceutical companies, a new trend has emerged over the past several years – using custom social media-like platforms to solve the critical, more specific communications challenges that are commonplace throughout the drug lifecycle. Called “online discussion platforms”, these solutions take the best features of social media communication, augment them with heavy compliance safeguards, and tailor them for specific use by life sciences professionals and their extended healthcare stakeholders. Discover how these platforms are being used to engage large groups.

    Read More

  • Pharmaceutical organizations are routinely wrestling with questions ranging from clinical insights, to market penetration and expansion, to access and coverage. Because steering committees bring together internal and external experts to provide periodic (and often unscheduled) feedback to the committee chairs throughout the year, they are highly effective in working through these issues. However, scheduling and logistical challenges can make steering committees hard to execute efficiently — particularly when factoring in time zone differences, travel, and scheduling coordination, and the need for quick and timely feedback. A leading pharmaceutical organization, facing these challenges, took an innovative approach to engaging their committee members. This case study examines how they did it.

    Read More

  • When preparing to initiate your first virtual event, whether it be a commercial or medical affairs advisory board, a clinical steering committee or even a patient advocacy session, following standard best practices can greatly increase your business results.

    Read More

  • A leading pharmaceutical’s commercial team was purposed with gaining insights on the ramifications of the treatment and expanded life expectancy related to a rare metabolic disease. As a key input to its efforts, the team decided to conduct a meeting with young adult patients, who would have first-hand knowledge and experience related to this subject.

    Read More

  • The U.S. government is increasingly focused on health care policy reforms, causing pharmaceutical companies to rethink their strategies and tactics in pursuing “share of scripts.” For pharmaceutical companies, these reforms represent a paradigm shift in the structure of the U.S. market, and call for innovative approaches to commercialization and pricing. In a new value-driven health care system, pharmaceutical companies’ drug therapies will need to provide products that demonstrate measurable value to a broader array of stakeholders – physicians, patients, and payers. As a result, companies are faced with an increased need for engaging in discussion across the entire stakeholder ecosystem.

    Read More

  • When optimally managed, the relationship between pharmaceutical organizations and healthcare professionals (HCPs) on the frontlines of patient care is bi-directional. A leading pharmaceutical organization’s joint medical affairs and commercial team, purposed with gaining insight and treatment perspectives about prescribing preferences and informational needs, was tasked with identifying an innovative approach to facilitating bi-directional discussions with leading clinicians around the country. This case study explains how they did it.

    Read More

  • Pharmaceutical companies are looking for convenient, cost-effective ways to engage physicians, patients, payers, and other external stakeholders throughout the drug development lifecycle. Online discussion technologies have been praised by teams and external stakeholders alike for being efficient and effective.  When first considering online discussion technologies, however, companies often have initial compliance concerns.

    Read More

  • A leading pharmaceutical organization’s medical affairs team facing a go-/no-go clinic trial decision desired to improve their collaboration process – and results. This case study explains how they did it.

    Read More

  • This infographic reflects just a sampling of recent participants’ sentiments, and why 19 of the top 20 pharmaceutical organizations are leveraging online discussion platforms across their medical affairs and commercial divisions.

    Read More

  • Pharmaceutical publication planning (often referred to as “Pub Planning”) plays a critical role in the dissemination of scientific and clinical data on a drug to healthcare professionals at scientific congresses, medical society meetings, and in peer reviewed medical journals. Such participation often includes multiple participants working from different geographic locations and related time-zones, which can lead to inefficiency and extended time required to complete related processes. A leading pharmaceutical organization’s medical affairs team facing these pub planning communication challenges desired to improve their collaboration process – and results.

    Read More

  • Based on an analysis of hundreds of Within3 programs from around the world, this Whitepaper will outline the current trends of how companies are choosing to engage with small teams of payers, patients, physicians, caregivers, and more.

    Read More

  • For Medical Science Liaisons (MSL) to be most effective in their roles, pharmaceutical organizations need to provide constant training and seamless resource updates and distribution. Engaging global MSL teams requires addressing the added communication barriers of diverse time-zones and languages. These dynamics have led to historically poor engagement levels and unsustainable travel costs and logistics…until now.

    Read More

  • Clinical trials make it possible for HCPs to apply the latest scientific advances to patient care. But clinical trials are not without challenges. Learn how a top 10 pharmaceutical company, preparing to conduct a multi-site clinical trial, benefited from the use of a digital collaboration solution that provided greater efficiencies in communications, ultimately maximizing the trial’s success.

    Read More

  • Building trust in the pharmaceutical industry is no easy feat. With the ever-changing healthcare regulations and transparency requirements, pharma companies receive negative and misleading media coverage that then impacts their business. In the following case study, a top 10 pharma company needed a solution that allowed them to meet regularly with advisors to discuss important in-depth issues. Within3 was able to provide that solution, with their virtual standing advisory panel, which allowed the pharma company to better understand, and react to, clinicians’ views of the media.

    Read More

  • The Physician Payment Sunshine Act is an initiative that requires manufacturers of drugs, medical devices and biologicals to report all payments and “transfers of value” given to US physicians and teaching hospitals. The program is intended to provide greater clarity into the relationships between pharmaceutical and device companies and healthcare providers.

    Read More

  • For the health and life science industry, budgetary planning is no easy feat. What has worked in years past might not work in the future. However, as the healthcare industry continues (and will continue) to evolve, some things will remain the same. The speakers bureau has been a longtime tactic in a healthcare marketing plan. While it may have seen a decline in usage over the years, the speakers bureau has evolved and will remain instrumental in healthcare providers’ research and ongoing education.

    Read More

  • Clinical trials are key to developing new methods to detect, treat and prevent diseases. Researchers use these trials to determine whether treatments are safe, effective and better than current therapies. Genomic testing in clinical trials can help bring genome-targeted medicines to patients quicker than ever before. This method promises to tailor treatments to an individual’s disease and molecular make-up rather than through the trial-and-error process. The following article defines genomic testing and how it is currently used in clinical trials.

    Read More

  • Engagement of patients and healthcare stakeholders is increasing recognized as essential to research effectiveness. However, attempting to convene advisors from all over the world at one time is not only unpredictable, but also costly. The following case study illustrates how a pharmaceutical company utilized a solution that allowed external stakeholders to assemble together within one platform, regardless of location or time zone. Within3 was able to provide a secure, online collaboration tool that allowed these stakeholders to provide valuable feedback in an easy-to-use, cost-efficient way.

    Read More

  • Compared to what was available only ten short years ago, today’s range of digital collaboration and communication options is astounding. Read more about how innovators are weaving digital solutions into the everyday fabric of their communications.

    Read More

  • Clinical decision-making involves intensive research, but also contains elements of uncertainty. Sometimes it requires physicians to use their best judgement when deciding treatment. This is why the more information a clinician has, the better the patient outcome. This case study illustrates how a top 10 pharma company utilized a solution that allowed external stakeholders to conveniently and candidly discuss how clinical research and patient outcomes directly impact pharmaceutical brands. Within3 was able to provide a secure, online discussion platform that allowed these stakeholders to provide feedback without disruption to their daily schedules.

    Read More

  • Stakeholder feedback provides critical input into priorities and resource use within the healthcare industry. Stakeholders collaboration offers real-world context that can guide business objectives and influence direction for pharmaceutical companies. In the following case study, a top 10 pharma company required a solution that allowed external stakeholders to efficiently and effectively discuss the impact of new guidelines on patient care. Within3 was able to provide a digital platform that allowed these stakeholders to add value while not disrupting their busy schedules.

    Read More

  • Life sciences continues to be an ever-evolving industry. And 2016 is no exception. From shifting focus to a value-based care model to rising healthcare costs to stricter regulations, the health and life sciences industry has certainly seen its share of changes this year.

    Read More

  • Collecting valuable data from clinical trials in paper form can be time-intensive, expensive and challenging. Electronic data capture (EDC) is a way to receive high quality clinical trial data while cutting costs and gaining a greater degree of security. However, according to research, only about half of regulated studies use EDC. This might be due to lack of knowledge or simply resistance to change. Whatever the reason, it is important to understand the advantages of EDC and how it is improving clinical trial studies. The following article offers 5 benefits of electronic data capture in clinical trial studies.

    Read More

  • When designing new drugs, pharmaceutical companies need to seek the input of key stakeholders – physicians, patients, payers. The goal is to achieve greater information exchange and data-mining capabilities about several key factors, including strategies payers employ to determine therapies and/or rein in costs.

    Read More

  • Clinical trials are known to involve hundreds of physicians and thousands of patients from all around the world at any given time. Many sites can also run multiple trials simultaneously, making it difficult to manage ongoing operations, while providing continuous support and seamless communications between all participants.

    Read More

  • In pharma, speakers bureaus are used for accelerating awareness and clinical expertise of important new treatments. Doctors and other HCPs use real-world clinical experience to educate and inform peers of different therapies for a particular disease. But, launching a speakers bureau is more than creating a PowerPoint presentation, contracting a speaker and inviting healthcare professionals to listen to your program.

    Read More

  • Gathering key stakeholders from different regions is not always feasible. It’s challenging to assemble 80-100 HCPs from around the country to discuss topics that impact the healthcare industry, such as updated treatment guidelines. But, in order to understand the implications of treatment decisions due to new guidelines, a pharma company needed to quickly engage multiple physicians from different parts of the country in meaningful dialogue.

    Read More

  • It seems as if all things are online now – shopping, education, entertainment – it was only a matter of time before the life sciences industry followed suit. Life science companies are constantly tasked with engaging healthcare professionals in order to help with all aspects of a drug lifecycle. The advent of online discussion platforms has allowed companies to engage with these stakeholders more frequently and at lower costs.

    Read More

  • When marketing in the pharmaceutical industry, you have to have a goal in mind. For years, it has always been financially focused. But, as the world of marketing has been reinventing itself, so, too, should its success metrics. Return on engagement could be the new guide to success. But, what does that mean exactly?

    Read More

  • Discover how a global, multi-brand pharmaceutical company used a digital collaboration solution to extend training, advance clinical collaboration, and enhance the brand knowledge and speaking skills in speakers bureaus.

    Executing a multi-media approach maximizes both live and digital channels to accomplish objectives. The digital collaboration solution provides speakers with valuable engagement opportunities, real time access to educational information, and advanced training to enhance their speaking skills on the brand. See the results after a 3 month period.

    Read More

  • Organizations that successfully innovate can produce miraculous interventions, technologies and therapies. Pharmaceutical companies are constantly tasked with being innovative, while reducing time and cost to market therapies. Innovation is about continuous process improvement; so, how can the industry effectively manage innovation?

    Read More

  • Patients have quickly become a new resource in efforts to improve the healthcare industry. As active participants in their own care, patients are more motivated to improve the system, engaging as collaborators in conducting clinical research. But, due to hectic schedules, patient advisors aren’t easy to come by.

    Read More

  • Knowing how to effectively research and develop a protocol is essential to the market approval of a clinical trial. In writing protocols, researchers engage scientists, HCPs, project managers and patients as each perspective makes an important contribution to the work being done.

    Read More

  • Enlisting the advice of a KOL is crucial to success. In this day and age, it is especially important to reach KOLs from across the world. But with time restrictions and budget constraints, gathering global feedback is no easy feat. A virtual advisory board platform allows for the ability to reach stakeholders from all over the world, improving insights while reducing costs.

    Read More

  • KOLs play a vital role in the health and life sciences industry. But with more and more hurdles, engaging them has become more difficult. Because of this, pharma companies must better understand KOLs and their motivators in order to provide new and better ways to gain their participation.

    Read More

  • Every business wants to continually evolve and improve. This is especially true in the pharma industry. Recognizing and resolving issues with patient treatment is at the top of a pharma company’s to do list. A leading pharma company wanted to better understand and improve their treatment protocol for a particular therapy.

    Read More

  • 3D printing has been around for years, mainly used in manufacturing. In more recent years, it has expanded into healthcare, where it’s been used to create custom prosthetics and dental implants. But, with the advent of the first FDA-approved 3D printed drug, this approach is expanding, allowing for more personalized healthcare at a lower cost.

    Read More

  • According to research, among the top 50 pharmaceutical companies worldwide, only about half of them actively participate on social media. On the other hand, 78% of Americans use social media and use it to get and information about health. So, why isn’t the pharma industry employing more social media to engage these consumers? While regulatory hurdles have stalled social media adoption in the past, now is the time to seize the opportunity.

    Read More

  • Modern technology has the ability to improve speakers bureau programs. At a high level, speakers bureau software can reduce costs and expertly organize and schedule dinner meetings, creating a strong foundation for effective and valuable programs. However, the challenges with existing programs has not allowed for the highest quality materials to be presented by the best educated speakers to the most extensive audiences.

    The following white paper identifies three crucial communication challenges within a speakers bureau program and how to address them.

    Read More

  • Pharma companies often recruit physicians to speak at events for the purpose of marketing specific therapies. These speakers’ programs leverage the credibility of the physicians to promote a pharmaceutical product. Although there are policies and training in place with respect to speakers’ programs, the presentations themselves tend to go stale. Because product teams often work in vacuums when producing materials, there is sometimes little-to-no KOL feedback when it is needed.

    Read More

  • The term “biomarker” refers to a measure of a biological state. Biomarkers are used to perform a clinical assessment, such as blood pressure, to monitor and predict health states in individuals. Biomarker-enabled research & development is maturing into a new methodology that allows drug makers to focus on patients with more precision.

    Read More

  • In a rapidly shifting healthcare environment, payers now sit at the epicenter, increasingly encouraged to make decisions about which drugs and treatments are prescribed. Their growing influence explains why previous marketing initiatives no longer get the best results. Market success now depends on the ability to reach and persuade payers.

    Read More

  • A premier healthcare group identified an information gap addressing hemophilia. Clinicians did not have a central resource to discuss and learn about the latest treatment options and guidelines, challenging patient cases and expert insight about the disease.

    Read More

  • In an effort to better serve the needs of patients, a pharmaceutical product team wanted to better understand the emotional implications of being diagnosed with, and starting treatment for, a severe chronic condition.

    Read More

  • The 505(b)(2) regulatory pathway is one of three categories of new drug applications (NDA). While the application requires full safety and effectiveness reports, it gives the FDA permission to use data not gathered by the NDA applicant, avoiding unnecessary duplicate analyses. Employing a 505(b)(2) regulatory strategy can offer significant benefits, encouraging innovation while offering a faster, more cost-efficient way to drug development.

    Read More

  • The Institute of Medicine (IOM) defines patient-centered care as, “Providing care that is respectful of and responsive to individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions.” Practicing patient-centered care improves patient outcomes while cultivating the quality of doctor-patient relationships. How can this translate to the marketing of pharmaceuticals?

    Read More

  • In the fall of 2015, the American Medical Association called for a ban on DTC (direct-to-consumer) advertising of prescription drugs and medical devices. The argument is based around the role that marketing costs allegedly play in the escalating drug prices. Here is a list of statistics in connection with the ban and how it could potentially affect the pharma industry.

    Read More

  • A successful pharmaceutical R&D process is one that reduces the time and cost necessary to bring a therapy to final regulatory approval and delivery to the patient. The following case study demonstrates how a top pharmaceutical company was able to gather intelligence in order to make informed business decisions through Within3’s secure, cost-efficient platform.

    Read More

  • 2015 was a wild ride for the pharma industry. We saw high profile mergers, landmark developments and, yes, damaging criticisms. These events, for better or for worse, are likely to shape the pharma landscape for 2016. Here are the top stories that consistently found their way into the headlines.

    Read More

  • Finding innovative ways to engage with stakeholders is a tricky business in the pharma industry. With strict industry regulations and vague guidance, it’s difficult to know what pharma companies can and cannot do on social media. However, social media is an important and strategic way to gather stakeholder insight and should be considered in pharmaceutical companies’ business plans. The following article highlights 10 best practices for opening dialogue with HCPs using social media.

    Read More

  • With the Sunshine Act requiring more transparency than before, and the pressure to bring costs down while still driving innovation, pharma companies have had to get creative. Digital collaboration solutions, like Within3’s virtual advisory platform, help efficiently solve the transparency problem while offering a platform that fosters communications.

    The following case study details the results of 18 virtual advisory boards in the oncology specialty.

    Read More

  • This past spring, the U.S. Food and Drug Administration approved the first biosimilar product in the U.S. Biosimilars are not new to the industry; they have been on the market in Europe since 2006. But, this newer practice has pharma watching closely as it could determine innovative, lower cost go-to-market therapies.

    The following article describes the argument, fallout and possible solutions for the introduction of biosimilars as therapeutic substitutions.

    Read More

  • Therapeutic substitution, while widely utilized, comes with its own set of obstacles. Although these substitutions may decrease costs for institutions and payers, it may create time-related costs for physicians and their patients. In the following article, we discuss the effect of therapeutic substitutions as a common practice in the healthcare industry.

    Read More

  • Pharma companies have struggled in the past few years realigning themselves to a new business model that addresses concerns brought on by the Physicians Sunshine Act, among other things. This case study describes how Within3 helped clients achieve business results with our highly successful online platform.

    Read More

  • The pharmaceutical industry has been at the center of controversy for some time now. Like everything in the pharmaceutical industry, there are complexities in the business, including drug pricing. This article illustrates how Within3 provides pharmaceutical companies a way to collaborate with stakeholders to respond quickly to the marketplace while being responsive to the unique needs of the industry.

    Read More

  • The role of a steering committee in the pharma industry is to guide the organization through projects, help to make decisions, provide strategic direction, and, ultimately, be an advocate for the initiatives involved. In the following case study, Within3 provided a virtual steering committee solution to help a top 25 pharmaceutical company better understand the effectiveness of their educational content for KOLs.

    Read More

  • Repurposing drugs is not new to the pharmaceutical industry. In fact, according to a report from the Congressional Budget Office, approximately two-thirds of new drug applications submitted to the FDA are modifications of existing drugs or their indications. Drug life-cycle development often includes extending the value and lifetime of a drug through innovative means such as finding a new indication of an existing drug. In the following case study, Within3 created a virtual advisory board to help a top 25 pharmaceutical company conduct R&D to better understand the pros and cons of pursuing a new indication for an existing molecule.

    Read More

  • Vaccination is the most effective method of preventing certain diseases, yet vaccination rates in certain parts of the US are slipping. The following case study describes how a top 10 pharma company was able to provide its stakeholders the ability to openly discuss vaccinations and their barriers.

    Read More

  • As pharmaceutical manufacturers are challenged with increasing operational efficiencies, reducing costs, and delivering more value, they are motivated to find new ways to address business objectives. Learn how to introduce a digital collaboration solution into your organization.

    Read More

  • The use of mobile technology has unquestionably increased in the health and life sciences industry in the past few years. More and more physicians are relying on their mobile devices in their everyday practice. In fact, 86% of clinicians now use their smartphones daily for medical research and patient communications.

    Read More

  • Pharmaceutical companies greatly depend on their relationships with payer organizations to leverage formulary access. As the power of the physician is reduced, payers have more influence over patient treatment. Click to see how Within3 delivered a secure platform to collaborate with these payers to better understand how formulary decision-making is executed.

    Read More

  • Not all moderators are created equal. Valuable moderators must be closely involved in the planning process and have an in-depth understanding of the client needs.

    In the following checklist, we provide some useful guidelines to look for when reviewing your next advisory board moderator.

    Read More

  • As medical and brand directors become more knowledgeable about digital collaboration, we are seeing a shift in the industry. Learn how to bring more innovative healthcare engagement solutions to your strategic planning.

    Read More

  • Now a reality, the Physician Payment Sunshine Act (PPSA) has life sciences companies grappling with new systems for tracking, compiling and reporting physician payments for regulatory disclosure. Discover new communication strategies to help engage HCPs while addressing privacy concerns.

    Read More

  • Read how Within3 introduced a culture of innovation to three Top 10 pharmaceutical companies, and helped them meet their business objectives by implementing a secure, regulatory compliant virtual advisory board for each.

    Read More

  • Pharmaceutical companies are changing their approach to strategies and long-term goals as a result of new data and analytics. The use of new research helps make big decisions when it comes to drug treatments and meeting other business objectives. A virtual advisory board can help pharma companies better collaborate with clinicians as they build out these new strategies.

    Read More